Publications by authors named "Hironobu Saneto"
Article Synopsis
- The study investigates the challenges of selective biliary cannulation during endoscopic retrograde cholangiopancreatography (ERCP), focusing on how different papillary morphologies can complicate the process.
- Researchers analyzed data from 776 patients to identify risk factors for cannulation difficulties, finding that certain types of papillae, the presence of periampullary diverticulum (PAD), and scope operability significantly impacted success rates.
- The study concluded that specific patterns can predict cannulation difficulties, helping to inform whether to use conventional or salvage techniques in treatment.
Article Synopsis
- The study examines changes in characteristics of hospitalized patients in Japan from 2010 to 2021, highlighting issues related to the country's aging population.
- Data from nearly 24,000 inpatients show an increase in patients aged over 75 and a rise in emergency admissions over the years.
- Notably, there was a decline in liver disease cases and a significant increase in biliary-pancreatic conditions and malignancies during the study period.
Background/aim: Unresectable recurrence after curative treatments for hepatocellular carcinoma (HCC) is a life-limited event. Although the IMbrave050 trial (IM050) showed a favorable reduction in recurrence with adjuvant immune-combination chemotherapy, inclusion criteria of the radiofrequency ablation (RFA) group were lower risk than that of the resection group. This study aimed to elucidate the clinical features of patients treated with RFA, which really need adjuvant-chemotherapy.
View Article and Find Full Text PDFArticle Synopsis
- The Virtual Baveno VII Consensus Workshop suggested a method to predict esophagogastric varices (EGVs) using liver stiffness and platelet counts, but this method requires equipment not available everywhere.
- The study analyzed 1,090 patients with hepatocellular carcinoma to identify clinical factors predicting significant EGV, focusing on simple blood tests rather than specialized equipment.
- Key findings established a REGS score based on platelet count and mALBI grades, allowing for EGV prediction without needing advanced tools, demonstrating increasing risk with higher REGS scores.
No reports of renal cancer in patients with Wilson's disease (WD) exist. We herein report a 37-year-old Japanese man diagnosed with WD who had been treated with d-penicillamine 9 years prior. Hepatocellular carcinoma had been diagnosed at 36 years old and treated with radiofrequency ablation therapy.
View Article and Find Full Text PDFIntroduction: The aMAP score is a prediction model for hepatocellular carcinoma (HCC) risk in chronic hepatitis patients. This study was conducted to elucidate the utility of this model for predicting initial recurrence of HCC in patients within the Milan criteria after undergoing curative treatment.
Methods: Patients with naïve HCC within the Milan criteria (n = 1,020) and treated from January 2000 to August 2022 were enrolled.
Background/Aim: For intermediate-stage hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC]-B) cases, transarterial chemoembolization (TACE) is recognized as the standard treatment, while systemic therapy is recommended for TACE-unsuitable HCC. However, because the curative potential is not high, this study was conducted to elucidate the potential outcomes of surgical resection (SR) for BCLC-B HCC cases. Materials/Methods: From January 2000 to July 2022, 70 patients with BCLC-B HCC treated with surgery as the initial treatment were enrolled (median age 67.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of surgical resection (SR) versus radiofrequency ablation (RFA) for treating initial recurrences of early-stage hepatocellular carcinoma (HCC) after previous treatments.
- Data was gathered from 371 patients over two decades, analyzing recurrence-free survival (RFS) and overall survival (OS) rates, revealing no significant differences between SR and RFA in these outcomes.
- The findings support the conclusions of the SURF trial, affirming that both SR and RFA have comparable therapeutic efficacy for this patient group.